Prostate cancer: F-18-fluorocholine PET-CT utility. [Cancer de la prostate : utilité de la TEP-TDM à la 18F-fluorocholine.]

Details

Serval ID
serval:BIB_F25EE3596E91
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Prostate cancer: F-18-fluorocholine PET-CT utility. [Cancer de la prostate : utilité de la TEP-TDM à la 18F-fluorocholine.]
Journal
Médecine Nucléaire
Author(s)
Boubaker A., Houzard C., Zouhair A., Got P., Orcurto M.V., Giammarile F.
ISSN
0928-1258
Publication state
Published
Issued date
2011
Peer-reviewed
Oui
Volume
35
Number
8
Pages
446-454
Language
french
Abstract
In oncology, positron emission computed tomography (PET/CT) has become an essential tool for initial staging, response evaluation and follow-up of cancer patients. Most of the frequent tumors (lung, breast, esophagus, and lymphomas) are highly avid for (18)F-fluorodeoxyglucose ((18)FDG), but prostate cancer has not demonstrated significant uptake of FDG. The development of new tracers labeled with (18)F such as choline analogs allowed already to obtain interesting results particularly in patients with biological relapse and inconclusive conventional imaging workup. The impact of (18)F-flurocholine PET/CT on patient management needs to be validated in large studies, but many centers use already this examination in order to guide further management, including radiotherapy planning. (C) 2011 Elsevier Masson SAS. All rights reserved.
Keywords
Fluorocholine, Prostate cancer, PET, Imaging, POSITRON-EMISSION-TOMOGRAPHY, F-18 FLUOROCHOLINE, LOCALIZATION
Web of science
Create date
29/09/2011 9:31
Last modification date
20/08/2019 16:19
Usage data